Machine learning approaches for the identification of real-world predictors of mepolizumab response

BACKGROUND: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. OBJECTIVE: Identify predictors of response to mepolizumab using machine learning techniques. METHODS: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. RESULTS: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. CONCLUSION: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-13
DOI
https://doi.org/10.1371/journal.pone.0362402
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Machine learning approaches for the identification of real-world predictors of mepolizumab response

Lingjiao Zhang, Rafael Alfonso‐Cristancho, Koyo Usuba, Natalie Nightingale et al.
1 links
PLoS ONE
Asthma and respiratory diseases
article

Machine learning approaches for the identification of real-world predictors of mepolizumab response

Lingjiao Zhang, Rafael Alfonso‐Cristancho, Koyo Usuba, Natalie Nightingale, Xinyang Liu, Tim Tian Yu Han, Ali Tehrani, Peter Howarth
article en

Abstract

BACKGROUND: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. OBJECTIVE: Identify predictors of response to mepolizumab using machine learning techniques. METHODS: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. RESULTS: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. CONCLUSION: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.

PLoS ONEVol. 21(11)
GlaxoSmithKline (United Kingdom) (GB)
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon